Enhancing FDA Oversight for Safer Eyedrops: New Powers and Challenges

by Madison Thomas
FDA Eyedrop Oversight

When purchasing over-the-counter eyedrops in the United States, consumers trust that these products are manufactured in clean, well-regulated facilities, adhering to the highest standards of quality and safety. However, recent recalls have raised concerns about the limited knowledge U.S. officials have regarding manufacturing conditions in foreign plants and their ability to intervene when issues arise.

The Food and Drug Administration (FDA) is now urging Congress to grant them additional powers, which include the authority to mandate drug recalls and require inspections of eyedrop manufacturers before their products are shipped to the U.S. While these proposed powers seem promising, experts caution that they may be ineffective without the allocation of more resources and staff for foreign inspections, a challenge that predates the COVID-19 pandemic.

David Ridley, a researcher from Duke University, highlights the concerning decline in FDA foreign inspections, with a staggering 79% decrease in 2022 compared to 2019. Although inspections have increased in the current year, they still fall significantly below pre-pandemic levels.

FDA spokesperson Jeremy Kahn emphasizes that while the FDA strives to inspect as many facilities as possible, the responsibility for product quality ultimately rests with the industry.

A pivotal moment in this discussion was the October recall of two dozen eyedrop brands, originating from a Mumbai plant that supplied products to major retailers such as CVS and Walmart. FDA inspectors discovered unsanitary conditions, including cracked floors and barefoot workers, during their first-ever visit to the facility. This inspection followed an earlier recall associated with a different Indian plant, which had never been inspected and had been linked to fatalities and vision loss cases.

To address these issues and improve the safety of eyedrop products, experts suggest three potential changes:

  1. Earlier Inspections: Unlike prescription medicines, over-the-counter products like eyedrops do not undergo preliminary reviews or inspections. They are governed by a system known as a monograph, which allows drugmakers to launch products rapidly once they attest to using the standard recipe. The FDA seeks the authority to require manufacturers of eyedrops and sterile products to provide at least six months’ notice before shipping products from a new factory, allowing inspectors to visit uncharted facilities.

  2. Requiring Recalls: The delay in recalling tainted eyedrops at the request of Indian manufacturer Kilitch Healthcare highlights the need for the FDA to have mandatory recall authority over drugs, similar to its authority over food and medical devices.

  3. Funding Foreign Inspectors: With drug manufacturing increasingly shifting to lower-cost countries like India and China, the FDA’s oversight of the global supply chain is critical. Experts suggest that Congress should address the challenges of recruiting and retaining overseas inspectors to ensure effective oversight.

In conclusion, the recent incidents involving eyedrop recalls have shed light on the need for enhanced FDA powers and resources to guarantee the safety and quality of such products. While the FDA’s proposals are a step in the right direction, addressing the challenges of foreign inspections and ensuring prompt recalls are crucial to safeguarding public health.

Frequently Asked Questions (FAQs) about FDA Eyedrop Oversight

What prompted the FDA to seek new powers for overseeing eyedrops?

The FDA sought new powers for overseeing eyedrops in response to repeated recalls and concerns about manufacturing conditions in foreign plants that supply these products. Recent incidents, including infections linked to eyedrops, highlighted the need for enhanced regulatory authority.

What specific powers is the FDA requesting from Congress?

The FDA is asking Congress for the authority to mandate drug recalls and to require inspections of eyedrop manufacturers before their products are shipped to the U.S. Additionally, they are seeking the ability to require manufacturers to provide at least six months’ notice before shipping products from a new factory.

Why is foreign inspection a challenge for the FDA?

Foreign inspections have been a challenge for the FDA due to resource limitations and the logistics of conducting inspections in countries where drug manufacturing has shifted, such as India and China. The COVID-19 pandemic further exacerbated these challenges.

How do over-the-counter products like eyedrops differ from prescription medicines in terms of regulation?

Over-the-counter products like eyedrops do not undergo the same level of regulatory scrutiny as prescription medicines. They are governed by a system called a monograph, which allows manufacturers to launch products quickly if they attest to using a standard recipe. This differs from prescription medicines, which undergo FDA review and factory inspections before approval.

What was the significance of the Mumbai plant inspection mentioned in the text?

The inspection of a Mumbai plant was significant because it was the first time FDA staff had visited the site. The inspection revealed unsanitary conditions, including cracked floors and barefoot workers. This inspection was prompted by an earlier recall of tainted eyedrops from a different Indian plant linked to deaths and vision loss cases.

How does the delay in recalls, as mentioned in the text, affect consumer safety?

The delay in recalling tainted eyedrops can pose a significant risk to consumer safety. In the case mentioned, the FDA had to wait almost three weeks for the products to be officially recalled because the manufacturer initially declined to cooperate. This delay could have allowed potentially harmful products to remain in circulation.

More about FDA Eyedrop Oversight

You may also like


InsightSeeker123 December 27, 2023 - 2:36 am

inspections were down 79% in 2022, dat’s crazy. covid messed everything up, huh?

PharmaExpert December 27, 2023 - 4:57 am

eyedrops diff from prescription meds? monograph vs. FDA review, interesting.

Reader27 December 27, 2023 - 6:33 am

fda needs these powers bad. recals for eyedrops are scary, need more safety!!

EyeHealthFan December 27, 2023 - 10:16 am

delay in recalls = bad for peeps. FDA must get recall power.


Leave a Comment


BNB – Big Big News is a news portal that offers the latest news from around the world. BNB – Big Big News focuses on providing readers with the most up-to-date information from the U.S. and abroad, covering a wide range of topics, including politics, sports, entertainment, business, health, and more.

Editors' Picks

Latest News

© 2023 BBN – Big Big News